Search | Clinical Trials Finder

Conditions: Carotid Stenosis
Interventions: Gadobutrol (Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 15
States / cities: Tucson, Arizona • Jacksonville, Florida • Savannah, Georgia + 12 more

Conditions: Cancer
Interventions: TLC178; Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Detroit, Michigan • The Bronx, New York

Conditions: Head and Neck Cancer
Interventions: ABY-029; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Human Immuno-deficiency Virus (HIV) Disease
Interventions: Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 43
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more

Conditions: Aspergillosis
Interventions: Anidulafungin, VER002; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: King of Prussia, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 35
States / cities: Huntsville, Alabama • La Jolla, California • Long Beach, California + 32 more

Conditions: Postoperative Nausea and Vomiting
Interventions: APD421, Placebo; Drug
Lead sponsor: Acacia Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Miami, Florida • Durham, North Carolina • Winston-Salem, North Carolina + 1 more

Conditions: Metastatic Cancer, Cancer, Solid Tumor
Interventions: BP31510 monotherapy, BP31510 in combination with chemotherapy; Drug
Lead sponsor: BPGbio; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Sunnyvale, California • New York, New York • Houston, Texas

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Valganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Beverly Hills, California • Paramount, California • San Francisco, California + 5 more

Conditions: Healthy
Interventions: Ramucirumab - IV, Placebo - IV, Ramucirumab - SC, Placebo - SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Hemophilia A
Interventions: Advate (Low Dose), Advate (High Dose), BIVV001 (Low Dose), BIVV001 (High Dose); Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 4 more

Conditions: Brain Diseases, Spinal Cord Diseases
Interventions: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), OptiMARK~0.1 mmol/kg BW; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 20
States / cities: Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more

Conditions: Safety
Interventions: Single intravenous doses of RC-01, Single intravenous doses of placebo, Multiple intravenous doses of RC-01, Multiple intravenous doses of placebo; Drug
Lead sponsor: Recida Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Morris Plains, New Jersey

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Glioma
Interventions: ABY-029; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Flucytosine, Fluconazole, Amphotericin B; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Miami, Florida • New Orleans, Louisiana • New York, New York + 3 more

Conditions: Pain on Propofol IV Injection
Interventions: lidocaine/tetracaine transdermal patch (NDC 43469-864-01), Gebauer's Ethyl Chloride; Device · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 6 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leptomeningeal Carcinomatosis
Interventions: RTA 744; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: LyphoMed; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rosemont, Illinois

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 1
States / cities: Morris Plains, New Jersey

Conditions: Solid Tumors, High Grade Gliomas, Lung Cancer, Head and Neck Cancer, Sarcoma, Renal Cell Carcinoma, Breast Cancer
Interventions: Fluciclatide Injection; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Magnetic Resonance Imaging
Interventions: Gadoxetate disodium (Eovist/Primovist, BAY86-4873); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 2 Months
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more

Search by objective public record fields.

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy

A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery

Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

The Study of Abatacept in Combination With Etanercept

Study of APD421 as PONV Treatment (Prior Prophylaxis)

BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors

Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection

A Study of Ramucirumab (LY3009806) in Healthy Participants

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Single and Multiple Dose Escalation Trial of an Intravenous Antibiotic RC-01

A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

A Microdose Evaluation Study of ABY-029 in Recurrent Glioma

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

In Children, Does Using a Synera Patch Decrease Pain When Injecting Propofol at Anesthesia Induction?

A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis

A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral / Oral Trimethoprim - Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia in AIDS

A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent